The present invention described in this application relates to compounds of the formulas Ia and Ib and their pharmaceutically acceptable salts, which are suitable for the treatment of prostate cancer, breast, colon, pancreas, chronic human lymphocytic leukemia, melanoma and other cancers. The present invention also includes pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula Ia or Ib or a pharmaceutically acceptable salt thereof. The invention described in this application also relates to methods for treating cancer of the prostate, breast, ovary, liver, kidney, colon, pancreas, chronic human lymphocytic leukemia, melanoma and other types of cancer. The invention described in this application additionally relates to methods of treating prostate cancer, breast, colon, pancreas, chronic lymphocytic leukemia, melanoma and other cancers, including the administration of a therapeutically effective amount of a compound that is a double antagonist of RAAPα and RAPδ . The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infection and HIV infection. The invention described in this application also relates to methods for the prevention, occurrence and / or recurrence of acute and chronic myeloid leukemia, as well as other types of cancer, including the administration of a therapeutically effective amount of a double antagonist, RAPPα and RAPPδ.Настоящее изобретение, описанное в данной заявке, относится к соединениям формул Ia и Ibи их фармацевтически приемлемым солям, которые пригодны для лечения рака предстательной железы, молочной железы, толстой кишки, поджелудочной железы, хронического лимфоцитарного лейкоза человека, меланомы и других видов рака. Настоящее изобретение также включает фармацевтические композиции, содержащие терапевтически эффективное количество соединения формулы Ia или Ib или его фармацевтически приемлемой соли. Указанное изобретение,
